Infosys (NYSE: INFY), a global leader in next-generation digital services and consulting, today announced a strategic partnership with University of Illinois Urbana-Champaign (UIUC) to develop new technologies and systems in precision medicine. Through this partnership Infosys also becomes a member of the Center for Computational Biotechnology and Genomic Medicine (CCBGM).
The adoption of new technologies by healthcare companies has significant benefits, including allowing caregivers to predict patients’ diseases and control prohibitive healthcare costs, in turn benefiting both patients and healthcare companies.
This partnership will combine Infosys’ strength in advanced machine learning, its artificial intelligence capabilities through the Infosys Nia platform, with UIUC’s expertise in computing systems, bioinformatics and genomic applications, to improve preventive care and enhance predictability of treatment outcomes of potential diseases.
“The partnership between Infosys and UIUC along with our membership in CCBGM opens up a lot of potential for Infosys’ work in the healthcare industry,” said Venky Ananth, Senior Vice President, Head of Healthcare at Infosys. “Not only do we have an opportunity to develop technologies and solutions that can improve and enhance patient care and management, but we also get a chance to collaborate with some of the finest minds on the new frontiers of healthcare innovation.”
“The future of precision medicine, which allows tailoring diagnosis and treatment to each patient in order to optimize outcome, is dependent on the ability to jointly analyze large datasets of heterogeneous biological (genomic, metabolic, neuroimaging, etc.) and clinical measures while incorporating key clinical domain knowledge. This is a complex challenge and will require innovations in both data-driven analytics and system design to succeed.” said Professor Ravishankar K Iyer, Electrical and Computer Engineering, University of Illinois and CoPI of the CCBGM.
About University of Illinois Urbana-Champaign
Founded in 1867, the University of Illinois at Urbana-Champaign is among the nation’s most prominent research institutions. At Illinois, our research drives life-changing innovations, permeates our classrooms and fuels our outreach. Illinois research fuels new ideas, new companies, and even new industries. Our faculty have developed many of the technologies that enable modern electronic devices, pioneered agricultural practices that feed the world, and shaped the government policies that protect the vulnerable in our society.
About the Center for Computational Biotechnology and Genomic Medicine (CCBGM)
The University of Illinois at Urbana-Champaign (UIUC) collaborated with the Mayo Clinic Center for Individualized Medicine to create the Center for Computational Biotechnology and Genomic Medicine (CCBGM). This unique collaboration brings together Mayo Clinic’s expertise in genetics, genomics, clinical care and individualized medicine with UIUC’s data management and computational technology expertise to achieve breakthroughs in precision medicine. The center is funded for five years through the National Science Foundation’s Industry/University Cooperative Research Centers (I/UCRC) program. Industry partners play a large role in the center.
Infosys is a global leader in next-generation digital services and consulting. We enable clients in 45 countries to navigate their digital transformation. With over three decades of experience in managing the systems and workings of global enterprises, we expertly steer our clients through their digital journey. We do it by enabling the enterprise with an AI-powered core that helps prioritize the execution of change. We also empower the business with agile digital at scale to deliver unprecedented levels of performance and customer delight. Our always-on learning agenda drives their continuous improvement through building and transferring digital skills, expertise, and ideas from our innovation ecosystem.
Visit www.infosys.com to see how Infosys (NYSE: INFY) can help your enterprise navigate your next.
Certain statements mentioned in this presentation concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2019. These filings are available at www.sec.gov Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the Company's filings with the Securities and Exchange Commission and our reports to shareholders. The Company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the Company unless it is required by law.